FI3818078T3 - Menetelmiä rekombinanttiproteiinien tuottamiseksi - Google Patents

Menetelmiä rekombinanttiproteiinien tuottamiseksi Download PDF

Info

Publication number
FI3818078T3
FI3818078T3 FIEP19745845.8T FI19745845T FI3818078T3 FI 3818078 T3 FI3818078 T3 FI 3818078T3 FI 19745845 T FI19745845 T FI 19745845T FI 3818078 T3 FI3818078 T3 FI 3818078T3
Authority
FI
Finland
Prior art keywords
nutrient medium
enriched
phase
culture system
viable cells
Prior art date
Application number
FIEP19745845.8T
Other languages
English (en)
Finnish (fi)
Inventor
Jianlin Xu
Andrew Yongky
Jun Tian
Michael C Borys
Zhengjian Li
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=67470657&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI3818078(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of FI3818078T3 publication Critical patent/FI3818078T3/fi

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018Culture media for cell or tissue culture
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/10Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14Specific host cells or culture conditions, e.g. components, pH or temperature
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00Specific components of cell culture medium
    • C12N2500/30Organic components
    • C12N2500/34Sugars

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
FIEP19745845.8T 2018-07-03 2019-07-02 Menetelmiä rekombinanttiproteiinien tuottamiseksi FI3818078T3 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862693606P 2018-07-03 2018-07-03
PCT/US2019/040298 WO2020010080A1 (en) 2018-07-03 2019-07-02 Methods of producing recombinant proteins

Publications (1)

Publication Number Publication Date
FI3818078T3 true FI3818078T3 (fi) 2024-05-14

Family

ID=67470657

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP19745845.8T FI3818078T3 (fi) 2018-07-03 2019-07-02 Menetelmiä rekombinanttiproteiinien tuottamiseksi

Country Status (23)

Country Link
US (2) US20210253996A1 (https=)
EP (2) EP3818078B1 (https=)
JP (3) JP7419273B2 (https=)
KR (2) KR20250153311A (https=)
CN (1) CN112839954A (https=)
AU (1) AU2019299358B2 (https=)
CA (1) CA3104684A1 (https=)
DK (1) DK3818078T3 (https=)
EA (1) EA202092904A1 (https=)
ES (1) ES2976708T3 (https=)
FI (1) FI3818078T3 (https=)
HR (1) HRP20240584T1 (https=)
HU (1) HUE066560T2 (https=)
IL (2) IL324666A (https=)
LT (1) LT3818078T (https=)
MX (1) MX2020013633A (https=)
PL (1) PL3818078T3 (https=)
PT (1) PT3818078T (https=)
RS (1) RS65472B1 (https=)
SG (1) SG11202012582QA (https=)
SI (1) SI3818078T1 (https=)
SM (1) SMT202400173T1 (https=)
WO (1) WO2020010080A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK181991B1 (en) * 2021-11-11 2025-05-15 Dsm Ip Assets Bv Combined fermentation process for producing one or more human milk oligosaccharide(s) (hmo(s)) in escherichia coli
WO2023242238A1 (en) * 2022-06-15 2023-12-21 UCB Biopharma SRL Cell culture processes
EP4339274B1 (en) 2022-09-13 2025-03-26 Sartorius Stedim Biotech GmbH Method for operating a bioprocess installation for production of a bioproduct
KR20240172522A (ko) * 2023-06-01 2024-12-10 (주)알테오젠 지속형 호르몬 수용체 길항제의 생산 방법

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4515893A (en) 1979-04-26 1985-05-07 Ortho Pharmaceutical Corporation Hybrid cell line for producing complement-fixing monoclonal antibody to human T cells
US5672347A (en) 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5091313A (en) 1988-08-05 1992-02-25 Tanox Biosystems, Inc. Antigenic epitopes of IgE present on B cell but not basophil surface
US5720937A (en) 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
DE68919361T2 (de) 1988-06-21 1995-05-24 Genentech Inc Therapeutische zusammensetzungen für die behandlung von myocard-infarkten.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ES2193136T3 (es) 1991-08-14 2003-11-01 Genentech Inc Variantes de inmunoglubina para receptores especificos de fc epsilon.
AU687755B2 (en) 1992-08-21 1998-03-05 Genentech Inc. Method for treating an LFA-1-mediated disorder
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
ES2108566T3 (es) 1993-12-10 1997-12-16 Genentech Inc Procedimientos para diagnosticar alergias y para seleccionar agentes terapeuticos antialergicos.
WO1995019181A1 (en) 1994-01-18 1995-07-20 Genentech, Inc. A METHOD OF TREATMENT OF PARASITIC INFECTION USING IgE ANTAGONISTS
US5707622A (en) 1994-03-03 1998-01-13 Genentech, Inc. Methods for treating ulcerative colitis
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
JPH11507535A (ja) 1995-06-07 1999-07-06 イムクローン システムズ インコーポレイテッド 腫瘍の成長を抑制する抗体および抗体フラグメント類
CA2242414C (en) 1996-01-23 2012-01-03 Genentech, Inc. Anti-cd18 antibodies for use against stroke
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
EP0941344B1 (en) 1996-11-27 2004-05-19 Genentech, Inc. HUMANIZED ANTI-CD11a ANTIBODIES
KR100816621B1 (ko) 1997-04-07 2008-03-24 제넨테크, 인크. 항-vegf 항체
ES2293682T5 (es) 1997-05-15 2011-11-17 Genentech, Inc. Anticuerpo anti-apo2.
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
ES2309012T3 (es) 1999-10-29 2008-12-16 Genentech, Inc. Composiciones del anticuerpo anti-psca y a sus procedimientos contra celulas cancerigenas que expresen psca.
US7335491B2 (en) * 2004-08-27 2008-02-26 Wyeth Research Ireland Limited Production of anti-abeta
AU2007294731B2 (en) * 2006-09-13 2014-04-17 Abbvie Inc. Cell culture improvements
HUE042314T2 (hu) 2011-02-07 2019-06-28 Cerenis Therapeutics Holding Sa Lipoprotein komplexek és azok gyártása és alkalmazásai
PT2837680T (pt) * 2011-07-01 2020-04-17 Amgen Inc Cultura celular de mamífero
WO2015095809A1 (en) * 2013-12-20 2015-06-25 Biogen Idec Ma Inc. Use of perfusion seed cultures to improve biopharmaceutical fed-batch production capacity and product quality
MA40021A (fr) * 2014-06-03 2015-12-10 Lupin Ltd Processus de culture cellulaire destiné à produire une protéine
AU2015269365A1 (en) * 2014-06-04 2016-12-15 Amgen Inc. Methods for harvesting mammalian cell cultures
US9813410B2 (en) 2014-06-26 2017-11-07 Rakuten, Inc. Information processing apparatus, information processing method, and information processing program

Also Published As

Publication number Publication date
US20210253996A1 (en) 2021-08-19
AU2019299358B2 (en) 2026-04-02
IL324666A (en) 2026-01-01
CA3104684A1 (en) 2020-01-09
IL279782A (en) 2021-03-01
CN112839954A (zh) 2021-05-25
WO2020010080A1 (en) 2020-01-09
PL3818078T3 (pl) 2024-04-29
EP4368699A2 (en) 2024-05-15
BR112020025623A2 (pt) 2021-03-23
IL279782B1 (en) 2026-01-01
SMT202400173T1 (it) 2024-07-09
JP2024050590A (ja) 2024-04-10
PT3818078T (pt) 2024-04-18
JP7419273B2 (ja) 2024-01-22
ES2976708T3 (es) 2024-08-07
EP3818078A1 (en) 2021-05-12
AU2019299358A1 (en) 2021-02-18
EP3818078B1 (en) 2024-02-28
DK3818078T3 (da) 2024-05-21
MX2020013633A (es) 2021-03-25
US20250171732A1 (en) 2025-05-29
JP2021529527A (ja) 2021-11-04
EP4368699A3 (en) 2024-09-11
KR20250153311A (ko) 2025-10-24
SI3818078T1 (sl) 2024-05-31
KR20210027427A (ko) 2021-03-10
HRP20240584T1 (hr) 2024-07-19
KR102870511B1 (ko) 2025-10-15
SG11202012582QA (en) 2021-01-28
LT3818078T (lt) 2024-04-25
RS65472B1 (sr) 2024-05-31
JP2026048825A (ja) 2026-03-17
HUE066560T2 (hu) 2024-08-28
EA202092904A1 (ru) 2021-04-22

Similar Documents

Publication Publication Date Title
FI3818078T3 (fi) Menetelmiä rekombinanttiproteiinien tuottamiseksi
CN103125275B (zh) 一种蛹虫草的栽培方法
Barghbani et al. Investigating the effects of several parameters on the growth of Chlorella vulgaris using Taguchi's experimental approach
Nishshanka et al. Wastewater-based microalgal biorefineries for the production of astaxanthin and co-products: current status, challenges and future perspectives
EA201270469A1 (ru) Способы культивирования клеток млекопитающих для получения белка
RU2008113220A (ru) Способ получения белков с использованием соединений, препятствующих старению
RU2009138226A (ru) Способы производства белка с использованием соединений, препятствующих старению
CN103773732B (zh) 一种化学成分确定的培养基、其应用及大规模培养哺乳动物细胞的生产工艺
Yin et al. The water footprint of biofilm cultivation of Haematococcus pluvialis is greatly decreased by using sealed narrow chambers combined with slow aeration rate
CN118879517B (zh) 解脂耶罗维亚酵母Yl590及其应用
JP2021529527A5 (https=)
CN104830691A (zh) 小球藻的培养方法
CN102311927A (zh) 一种酿酒酵母高密度发酵培养基和酿酒酵母高密度发酵方法
KR101525319B1 (ko) 신규한 마이크래티니엄 이너멈 nlp-f014 균주 및 이의 용도
CN107604026B (zh) 一种提高蛹虫草菌液体发酵虫草素产量的方法
CN101182471B (zh) 蛹虫草的一种高效培育方法
CN105483014A (zh) 发酵法高密度培养小球藻生产工艺
KR20180054344A (ko) 와이셀라 시바리아 균주의 대량 생산 방법 및 상기 균주의 배양용 배지 조성물
CN112210525A (zh) 一种无血清培养体系及其在细胞培养肉中的应用
CN109576212B (zh) 高密度接种培养中种子细胞的培养方法及其应用
CN103540534A (zh) 高蛋白沙漠绿藻的工业化培养方法
CN104004814A (zh) 采用动物细胞流加培养方式精确控制单克隆抗体产品质量的方法
CN108913635B (zh) 一种生产甘油葡萄糖苷过程中恢复蛋白质含量的方法
CN102776148A (zh) 一种昆虫细胞生长用培养基
RU2012109240A (ru) Способ культивирования мышечных клеток in vitro для получения биомассы, используемой для производства мясных пищевых продуктов